Arh Research LLC — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$584,617	23
2024	Research	$472,039	25
2023	Research	$126,995	6

Breakdown

Who paid Research payments · program years 2023–2025

Novartis Pharmaceuticals Corporation $770,286 15 payments
Eli Lilly and Company $160,087 2 payments
Amgen Inc. $139,932 2 payments
Janssen Research & Development, LLC $84,208 34 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $29,138 1 payment

Studies the money was for Research payments · program years 2023–2025

A Randomized, Double-Blind, Placebo Controlled, 3-Arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (Neptunus-2) $255,030 3 payments
A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease $203,946 2 payments
Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Psa) $146,650 1 payment
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) $145,745 2 payments
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity $139,782 1 payment
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent $84,208 34 payments
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome $70,626 2 payments
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 MG Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (Gca) $38,161 2 payments
Phase 2, Multicenter, Randomized, Double-Blind,Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Active Primary Sjgrens Syndrome (PSS) $29,138 1 payment
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) $27,630 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.